PCSK9 inhibition for patients with and without prior coronary revascularization: Potential additional benefit of a novel therapeutic agent

被引：2

作者：

Navarese, Eliano P. ^{[1
,2
,3
,4
]}

Raggi, Paolo ^{[4
,5
]}

机构：

[1] INOVA Heart & Vasc Inst, Fairfax, VA USA

[2] Mater Dei Hosp, Cardiovasc Res Ctr, Intervent Cardiol & Cardiovasc Res, Bari, Italy

[3] SIRIO Med Network, Milan, Italy

[4] Mazankowski Alberta Heart Inst, 8440 112 St,5A9-014, Edmonton, AB T6G 2B7, Canada

[5] Univ Alberta, Dept Med, Edmonton, AB, Canada

来源：

关键词：

PCSK9; Lipid lowering; Lipoproteins; Low density lipoprotein cholesterol; LIPOPROTEIN(A);

D O I：

10.1016/j.atherosclerosis.2018.07.038

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：177 / 178

页数：2

共 2 条

[1] Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol
Schwartz, Gregory G.
Szarek, Michael
Bittner, Vera A.
Diaz, Rafael
Goodman, Shaun G.
Jukema, J. Wouter
Landmesser, Ulf
Lopez-Jaramillo, Patricio
Manvelian, Garen
Pordy, Robert
Scemama, Michel
Sinnaeve, Peter R.
White, Harvey D.
Steg, Ph Gabriel
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2021, 78 (05) : 421 - 433
[2] Realizing the Potential of PCSK9 Inhibition A Novel Oral Macrocyclic Peptide on the Horizon
Chapman, M. John
Packard, Chris J.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2023, 81 (16) : 1565 - 1568